Form 4: Tarsus CHRO Whitfield Vests 23,909 Shares

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, acquired 23,909 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc. (TARS), acquired 23,909 shares of common stock on March 15, 2026.
• The acquisition resulted from the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Ms. Whitfield directly beneficially owns 47,302 shares of Tarsus Pharmaceuticals common stock.
• RSUs granted on March 9, 2022, totaling 4,463 units, fully vested and settled on March 15, 2026, with no remaining unvested units from this grant.
• From RSUs granted on March 8, 2023, 7,248 units vested on March 15, 2026, with 7,249 units remaining unvested.
• From RSUs granted on March 7, 2024, 7,176 units vested on March 15, 2026, with 14,351 units remaining unvested.
• From RSUs granted on March 5, 2025, 5,022 units vested on March 15, 2026, with 15,067 units remaining unvested.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting a routine executive compensation outcome that increases insider ownership and aligns executive incentives with company performance, without indicating any new strategic developments.

Positives

• The transaction increases the direct beneficial ownership of common stock by a key executive, aligning management interests with those of shareholders.
• The vesting of RSUs is a standard component of executive compensation, indicating continued retention and incentivization of the Chief Human Resources Officer.

Future Outlook

Dianne C. Whitfield has remaining unvested Restricted Stock Units from grants made in 2023, 2024, and 2025, which are scheduled to vest on March 15th of subsequent years through 2029, subject to her continuous service.

Industry Context

StockSavvy.ai notes that the vesting and settlement of Restricted Stock Units for executives is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of long-term incentive compensation plans designed to align executive interests with shareholder value creation and promote retention.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through higher direct stock ownership.

Next Steps

• Future tranches of Restricted Stock Units granted on March 8, 2023, are scheduled to vest on March 15th of 2027.
• Future tranches of Restricted Stock Units granted on March 7, 2024, are scheduled to vest on March 15th of 2027 and 2028.
• Future tranches of Restricted Stock Units granted on March 5, 2025, are scheduled to vest on March 15th of 2027, 2028, and 2029.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, insider transaction, RSU vesting, executive compensation, Dianne C. Whitfield, stock plan